PRESS RELEASE FROM OD-OS, INC.

University Retina and Macula Associates of Oak Forest, Illinois First in World to Adopt Navilas® Navigated Photocoagulation to Treat Diabetic Eye Disease

September 14, 2010

San Francisco, CA and Berlin, Germany – September 14, 2010 – OD-OS,
developer of Retina Navigation, announced today that University Retina and Macula Associates of Oak Forest Illinois has become the first site in the world to adopt Navigated Photocoagulation to treat their diabetic retinopathy patients. Recently cleared by the FDA, the Navilas® navigated photocoagulation system utilizes a novel registration technology to follow
eye movement during surgery and deliver laser energy precisely at intended treatment sites.

OD-OS, developer of the Navilas navigated photocoagulation system, is currently introducing this innovative technology to the U.S. ophthalmology community and establishing an exclusive network of collaborating retinal specialists, called Centers of Excellence, whose collective aim is to further improve patient care in the treatment of diabetic retinopathy.

The Navilas system integrates digital retina imaging, integrated laser planning, target assisted laser delivery, and electronic documentation overcoming many of the limitations of conventional slit lamp mounted and manually aimed retina lasers. The Navilas is currently available in the United States, Germany and select international markets and will become
available in additional markets as OD-OS develops its global training and service support network.

Rama D. Jager, M.D., F.A.C.S., primary physician at the University Retina and Macula Associates P.C. and Clinical Assistant Professor of Ophthalmology & Visual Science at University of Chicago Hospitals, has become the first to establish a Navilas Center of Excellence. He is positive that navigated photocoagulation will set new standards for the
treatment of retinal disorders: “Providing the best possible care to our patients is our top priority and the Navilas system will serve as an important step in optimizing the level of care we provide our patients in helping them with their vision. We are now better suited to provide
solutions to difficult clinical challenges in diabetic retinopathy and are pleased to be the first in the world to offer this level of care.”

“In retina surgery, a fraction of a millimeter means a lot. Navilas is the first photocoagulation device to allow precise localized targeting of retinal pathologies and adjust for patient eye movement during surgery. This feature is of exquisite importance when treating near areas responsible for central vision,” added Seenu Hariprasad, M.D., Associate
Professor of Ophthalmology and Visual Science, Director of Clinical Research and Chief, Vitreoretinal Service at University of Chicago Hospitals who was instrumental in early clinical evaluations of the technology. “The addition of the Navilas navigated photocoagulation
device to our community will provide patients with diabetic retinopathy the best possible care available.”

Following the agreement with Dr. Jager, OD-OS has completed its first installation of Navilas after its commercial launch this summer. Peter Falzon, CCO and President of OD-OS, Inc. commented, “Establishing the first Center of Excellence with Dr. Jager is of paramount significance to OD-OS and marks our first collaborative stride to further improve patient care in the treatment of diabetic retinopathy. We have developed Navilas in close dialog with our customers and are confident that we can optimally cater to the focused needs of the retina specialist. We will continue to develop unique solutions as a provider of navigated retina therapies and thereby contribute to the more effective and efficient treatment of retinal
diseases.”

For more information about Navilas or the Center of Excellence program, please contact:

Zara Barlas
Marketing Communications Account Manager, KAMCommunications
+44(0) 7876 330 806
zbarlas@kamcommunications.com

or

Levi Hall
Director of Marketing, OD-OS
+1 (415) 376-7657
levi.hall@od-os.com

For more information about the University Retina and Macula Associates of Oak Forest Illinois, please contact:

Rama D. Jager, M.D., M.B.A., F.A.C.S.
President, University Retina & Macula Associates, P.C.
Clinical Assistant Professor of Ophthalmology & Visual Science
Department of Surgery
University of Chicago Hospitals
(708) 687-2222
questions@uretina.com

###
About Navilas
Navilas integrates real-time, full-fundus view digital imaging and retinal photocoagulation delivery in a single device. Fundus images are acquired and annotated by the physician using a touch screen, creating a detailed treatment plan which becomes available as a live overlay on the retina during treatment. As laser treatment is delivered, Navilas employs a proprietary technology that registers and follows eye movement to enable the surgeon to accurately target the selected position. This new treatment paradigm, Navigated Photocoagulation, integrates imaging, planning and registered treatment with novel digital documentation capabilities for the
treatment of retina disorders. The Navilas system is now available for sale to physicians in the US, Germany and select international markets.

About OD-OS

OD-OS is an ISO 9001 and ISO 13485 certified medical device company headquartered in Teltow/Berlin, Germany. Its U.S. operation, responsible for marketing, sales and support, is located in San Francisco, CA. OD-OS is a subsidiary of SensoMotoric Instruments (SMI), the technology leader in eye tracking and registration solutions for refractive laser surgery. Over the past 15 years, SMI has supplied technology to most major refractive laser manufacturers. In 2008, after more than 4 years of development creating Retina Navigation within SMI, the
core development team was spun-out into OD-OS and charged with resources and ophthalmic industry experts to bring Retina Navigation with its first product, Navilas, to the market. For more information visit www.od-os.com or in the U.S. call +1 (877) 628-6367 and in Europe call +49 (3328) 31 282-100.

Posted on 09/14/2011